Recent Investment Analysts’ Ratings Updates for AstraZeneca (AZN)

A number of research firms have changed their ratings and price targets for AstraZeneca (LON: AZN):

  • 9/23/2019 – AstraZeneca was given a new GBX 7,900 ($103.23) price target on by analysts at JPMorgan Chase & Co.. They now have a “buy” rating on the stock.
  • 9/20/2019 – AstraZeneca had its “hold” rating reaffirmed by analysts at Liberum Capital.
  • 9/18/2019 – AstraZeneca had its “buy” rating reaffirmed by analysts at Shore Capital.
  • 9/16/2019 – AstraZeneca had its “overweight” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a GBX 7,900 ($103.23) price target on the stock.
  • 9/13/2019 – AstraZeneca had its price target raised by analysts at Barclays PLC from GBX 8,000 ($104.53) to GBX 8,200 ($107.15). They now have an “overweight” rating on the stock.
  • 9/13/2019 – AstraZeneca was given a new GBX 8,500 ($111.07) price target on by analysts at Bank of America Corp. They now have a “buy” rating on the stock.
  • 9/11/2019 – AstraZeneca had its “buy” rating reaffirmed by analysts at Citigroup Inc. They now have a £100 ($130.67) price target on the stock, up previously from GBX 7,000 ($91.47).
  • 9/10/2019 – AstraZeneca had its “sell” rating reaffirmed by analysts at UBS Group AG. They now have a GBX 5,700 ($74.48) price target on the stock.
  • 9/10/2019 – AstraZeneca had its “buy” rating reaffirmed by analysts at Societe Generale.
  • 9/9/2019 – AstraZeneca had its price target raised by analysts at Deutsche Bank AG from GBX 7,600 ($99.31) to GBX 7,800 ($101.92). They now have a “buy” rating on the stock.
  • 9/9/2019 – AstraZeneca was given a new GBX 7,900 ($103.23) price target on by analysts at JPMorgan Chase & Co.. They now have a “buy” rating on the stock.
  • 9/6/2019 – AstraZeneca had its price target raised by analysts at Barclays PLC from GBX 7,800 ($101.92) to GBX 8,000 ($104.53). They now have an “overweight” rating on the stock.
  • 9/6/2019 – AstraZeneca had its “overweight” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 9/3/2019 – AstraZeneca was given a new GBX 7,900 ($103.23) price target on by analysts at JPMorgan Chase & Co.. They now have a “buy” rating on the stock.
  • 9/2/2019 – AstraZeneca was given a new GBX 5,500 ($71.87) price target on by analysts at Goldman Sachs Group Inc. They now have a “sell” rating on the stock.
  • 9/2/2019 – AstraZeneca was upgraded by analysts at Deutsche Bank AG to a “buy” rating. They now have a GBX 7,600 ($99.31) price target on the stock, up previously from GBX 7,200 ($94.08).
  • 8/29/2019 – AstraZeneca had its “neutral” rating reaffirmed by analysts at Jefferies Financial Group Inc.
  • 8/28/2019 – AstraZeneca had its “hold” rating reaffirmed by analysts at Liberum Capital. They now have a GBX 6,400 ($83.63) price target on the stock.
  • 8/28/2019 – AstraZeneca was given a new GBX 7,900 ($103.23) price target on by analysts at JPMorgan Chase & Co.. They now have a “buy” rating on the stock.
  • 8/27/2019 – AstraZeneca had its “buy” rating reaffirmed by analysts at Shore Capital.
  • 8/26/2019 – AstraZeneca was given a new GBX 5,500 ($71.87) price target on by analysts at Goldman Sachs Group Inc. They now have a “sell” rating on the stock.
  • 8/21/2019 – AstraZeneca had its “sell” rating reaffirmed by analysts at UBS Group AG.
  • 8/21/2019 – AstraZeneca was given a new GBX 7,900 ($103.23) price target on by analysts at JPMorgan Chase & Co.. They now have a “buy” rating on the stock.
  • 8/20/2019 – AstraZeneca was given a new GBX 5,500 ($71.87) price target on by analysts at Goldman Sachs Group Inc. They now have a “sell” rating on the stock.
  • 8/20/2019 – AstraZeneca had its “hold” rating reaffirmed by analysts at Liberum Capital.
  • 8/20/2019 – AstraZeneca had its “buy” rating reaffirmed by analysts at Shore Capital.
  • 8/16/2019 – AstraZeneca had its price target raised by analysts at Barclays PLC from GBX 7,600 ($99.31) to GBX 7,800 ($101.92). They now have an “overweight” rating on the stock.
  • 8/15/2019 – AstraZeneca was given a new GBX 7,900 ($103.23) price target on by analysts at JPMorgan Chase & Co.. They now have a “buy” rating on the stock.
  • 8/14/2019 – AstraZeneca had its “sell” rating reaffirmed by analysts at UBS Group AG. They now have a GBX 5,700 ($74.48) price target on the stock, up previously from GBX 5,400 ($70.56).
  • 8/14/2019 – AstraZeneca had its “hold” rating reaffirmed by analysts at Liberum Capital.
  • 8/12/2019 – AstraZeneca had its “overweight” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 8/9/2019 – AstraZeneca had its “overweight” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a GBX 7,900 ($103.23) price target on the stock.
  • 8/9/2019 – AstraZeneca was given a new GBX 7,600 ($99.31) price target on by analysts at Barclays PLC. They now have a “buy” rating on the stock.
  • 8/9/2019 – AstraZeneca had its “buy” rating reaffirmed by analysts at Shore Capital.
  • 8/7/2019 – AstraZeneca had its “hold” rating reaffirmed by analysts at Liberum Capital.
  • 8/5/2019 – AstraZeneca had its price target raised by analysts at Goldman Sachs Group Inc from GBX 5,000 ($65.33) to GBX 5,500 ($71.87). They now have a “sell” rating on the stock.
  • 7/30/2019 – AstraZeneca was given a new GBX 7,900 ($103.23) price target on by analysts at JPMorgan Chase & Co.. They now have a “buy” rating on the stock.

Shares of AstraZeneca stock traded up GBX 83 ($1.08) during trading hours on Wednesday, hitting GBX 7,328 ($95.75). 1,900,764 shares of the company’s stock traded hands, compared to its average volume of 2,310,000. The stock has a 50 day simple moving average of GBX 7,204.01 and a 200-day simple moving average of GBX 6,434.79. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 144.48. The company has a market cap of $96.13 billion and a PE ratio of 42.80. AstraZeneca plc has a twelve month low of GBX 5,312 ($69.41) and a twelve month high of GBX 7,583 ($99.09).

The firm also recently announced a dividend, which was paid on Monday, September 9th. Stockholders of record on Thursday, August 8th were paid a dividend of GBX 71.90 ($0.94) per share. The ex-dividend date was Thursday, August 8th. This represents a dividend yield of 1.07%. AstraZeneca’s dividend payout ratio is presently 1.28%.



AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Story: What is Green Investing?

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.